A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).

NCT Number	NCT06220201
Lead Sponsor	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Collaborators: Celgene Corporation
Conditions	Multiple Sclerosis, Myasthenia Gravis
Enrollment	120 participants
Start Date	2024-03-28
Primary Completion	2027-07-15 (estimated)
Study Completion	2027-07-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-03